Is Godavari Drugs Ltd (530317) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Godavari Drugs Ltd is a average quality company .

Is Godavari Drugs Ltd (530317) undervalued or overvalued?

The key valuation ratios of Godavari Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Godavari Drugs Ltd (530317) share price return in the past 10 years?

Godavari Drugs Ltd share price has appreciated 10.7% annually (CAGR) over the past ten years.

Is Godavari Drugs Ltd (530317) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Godavari Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Godavari Drugs Ltd (530317)?

Company share prices are keep on changing according to the market conditions. The current trading price of Godavari Drugs Ltd (530317) on 17-Apr-2026 16:59:59 at 16:59 is 125.15.

What is the P/E ratio of Godavari Drugs?

The latest standalone P/E ratio of Godavari Drugs as of 17-Apr-2026 is 34.33.

What is the P/B ratio of Godavari Drugs Ltd (530317)?

The latest standalone P/B ratio of Godavari Drugs Ltd (530317) as of 17-Apr-2026 is 2.60.

What is the 52-week high and low of Godavari Drugs Ltd (530317)?

The 52-week high of Godavari Drugs Ltd (530317) is Rs. 129.85 and the 52-week low is Rs. 69.70.

Godavari Drugs Ltd (530317) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Godavari Drugs Ltd (530317)
Brand: Godavari Drugs

Godavari Drugs Ltd (530317) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Godavari Drugs Ltd (530317)

BSE: 530317 NSE:

Key Metrics

Market Cap

₹127 Cr.

P/E Ratio

34.33

Price to Book (P/B)

2.60

Price to Sales (P/S)

1.29

EV/EBITDA

17.62

Return on Capital Employed (ROCE)

10.13%

Current Price

₹125.2

Return on Equity (ROE)

10.64%

Return on Assets (ROA)

3.15%

Operating Profit Margin

10.7%

Net Profit Margin

3.86%

Gross Profit Margin

7.1%

Book Value per Share

₹48.1

Sales Growth (YoY)

-27.67%

Sales Growth (3 Years)

-11.06%

Operating Profit Growth (1 Year)

-11.05%

Operating Profit Growth (3 Years)

1.57%

Net Profit Growth (1 Year)

-21.08%

52-Week Low / High

₹70 / 130

Net Profit Growth (3 Years)

-5.83%

Dividend Yield

0.00%

Promoter Holding

52.61%

Pledged shares (%)
of Promoter's holding (%)

0.22%

Check Before You Invest

Q.1 Revenue growth of Godavari Drugs Ltd?

Godavari Drugs Ltd revenue growth is -27.7% for FY-2025 , which is below its 5 year CAGR of 3.4% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Godavari Drugs Ltd?

Promoters hold 52.61% of the Godavari Drugs Ltd, with 0.22% of their stake pledged, indicating low pledge risk.

Q.1 Revenue growth of Godavari Drugs Ltd vs industry peers?

Godavari Drugs Ltd revenue CAGR is 3.44% , compared to the industry median CAGR of 5.54% , indicating stable growth and maintaining its market share.

Q.1 Which industry/sub-sector does Godavari Drugs Ltd belong to?

Godavari Drugs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Godavari Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 10.9% based on the current price.

DeciZen - make an informed investing decision on Godavari Drugs

Based on:

Data

Overall Rating ⓘ
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

3. Price Trend

Godavari Drugs stock performance

Key Ratios

Is Godavari Drugs Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	15.8%	16.9%	11%	12.1%	11.8%	17.6%	18.4%	12.4%	12.6%	10.1%	-
Value Creation Index ⓘ	0.1	0.2	-0.2	-0.1	-0.2	0.3	0.3	-0.1	-0.1	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	71.1	75.6	64.5	83.5	95.7	123	161	160	157	113	98
Sales YoY Gr.	-	6.3%	-14.8%	29.6%	14.6%	28.2%	31.3%	-0.9%	-1.8%	-27.7%	-
Adj EPS ⓘ	1.7	1.7	0.8	1.6	2.6	5.3	7.2	6.5	7.6	6.1	3.7
YoY Gr.	-	2.4%	-53.2%	91.4%	68.4%	103.5%	35.2%	-9.6%	17.1%	-20.1%	-
BVPS (₹) ⓘ	19.1	21.5	22.6	24.2	26.9	32.4	39.4	44.4	51.7	57.6	48.1
Adj Net Profit ⓘ	1.3	1.3	0.6	1.2	2	4	5.4	4.9	5.7	4.6	4
Cash Flow from Ops. ⓘ	-4.5	5.2	3.8	3.7	6.2	1.3	11.2	13.2	18.4	11.2	-
Debt/CF from Ops. ⓘ	-3.4	3.1	5	5.9	4.4	22.9	2.1	4.3	3.1	5.8	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5.3%	3.4%	-11.1%	-27.7%
Adj EPS ⓘ	15.3%	18.4%	-5.4%	-20.1%
BVPSⓘ	13%	16.4%	13.5%	11.3%
Share Price	10.7%	19.3%	16.9%	31.3%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	9.3	8.5	3.7	6.6	10.2	17.9	20	15.5	15.8	11.1	6.9
Op. Profit Mgn % ⓘ	6.4	7	6.3	6.6	6.3	8	7.2	7.4	8.6	10.7	10.7
Net Profit Mgn % ⓘ	1.8	1.7	1	1.4	2.1	3.3	3.4	3.1	3.7	4	3.8
Debt to Equity ⓘ	1.1	1	1.1	1.2	1.4	1.3	0.8	1.7	1.5	1.5	-
Working Cap Days ⓘ	154	180	249	221	219	188	157	179	200	266	144
Cash Conv. Cycle ⓘ	58	60	78	72	75	70	50	82	113	135	8

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	3.7	-
TTM Sales (₹ Cr.)	98.2	-
BVPS (₹) ⓘ	48.1	-
Reserves (₹ Cr.) ⓘ	39	-
P/BV ⓘ	2.60	-
PE ⓘ	34.33	-

From the Market
52 Week Low / High (₹)	69.70 / 129.85
All Time Low / High (₹)	1.00 / 155.00
Market Cap (₹ Cr.)	127
Equity (₹ Cr.)	10.1
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

1.25

0.25

0.22

* Pledged shares as % of Promoter's holding (%)

Valuation of Godavari Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	71	76	64	84	96	123	161	160	157	113
Operating Expenses ⓘ +	67	70	60	78	90	113	150	150	143	102
Manufacturing Costs	4	7	5	6	6	8	10	10	12	10
Material Costs	59	59	49	65	77	97	130	128	121	82
Employee Cost	2	2	3	3	3	4	5	5	5	5
Other Costs ⓘ	2	2	3	4	3	4	5	7	6	4
Operating Profit ⓘ	4	5	4	5	6	10	11	10	13	12
Operating Profit Margin (%)	6.3%	6.9%	6.3%	6.6%	6.3%	8.0%	7.0%	6.2%	8.5%	10.4%
Other Income ⓘ +	0	1	1	0	0	0	0	1	1	1
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	-0	0
Interest ⓘ	2	3	2	3	3	3	3	4	5	5
Depreciation ⓘ	1	1	1	1	1	1	2	2	2	2
Profit Before Tax ⓘ	2	3	1	2	2	6	7	5	7	6
Tax ⓘ	1	1	0	1	0	2	2	1	1	1
Profit After Tax	1	2	1	1	2	4	5	4	6	4
PAT Margin (%)	1.9%	2.4%	1.3%	1.5%	2.1%	3.4%	3.3%	2.4%	3.5%	3.9%
Adjusted EPS (₹)	1.8	2.4	1.1	1.6	2.7	5.5	7.0	5.0	7.4	5.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	14	16	17	18	20	24	30	33	39	43
Share Capital ⓘ	8	8	8	8	8	8	8	8	8	8
Reserves ⓘ	7	9	10	11	13	17	22	26	31	36
Debt +	15	16	18	21	26	28	20	55	56	62
Long Term Debt	4	4	7	8	11	14	12	12	11	24
Short Term Debt	12	11	12	13	15	14	9	43	44	38
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	17	20	23	30	30	30	43	25	32	29
Others Liabilities ⓘ	3	4	5	4	7	9	8	8	9	9
Total Liabilities ⓘ	51	56	63	74	84	91	101	121	135	143
Fixed Assets
Net Fixed Assets ⓘ +	9	13	15	15	14	22	26	25	27	33
Gross Block	25	30	33	34	34	44	50	46	47	49
Accumulated Depreciation	16	17	18	19	20	22	23	21	20	17
CWIP ⓘ	1	0	1	2	9	1	0	9	18	30
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	11	11	13	16	18	15	10	20	21	28
Trade Receivables	25	24	27	34	36	45	56	58	59	42
Cash Equivalents	1	1	2	2	1	2	2	3	3	2
Others Assets ⓘ	5	6	6	5	6	7	7	7	7	8
Total Assets ⓘ	51	56	63	74	84	91	101	121	135	143

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-5	5	4	4	6	1	11	13	18	11
PBT ⓘ	1	3	1	6	2	6	7	5	7	6
Adjustment ⓘ	1	3	3	-0	4	4	4	5	6	6
Changes in Working Capital ⓘ	-6	0	0	-1	1	-7	2	4	6	1
Tax Paid ⓘ	0	-1	-1	-0	-0	-2	-2	-1	-1	-1
Cash Flow From Investing Activity ⓘ +	-2	-3	-3	-2	-7	-1	-5	-9	-13	-20
Capex	-2	-4	-4	-3	-7	-2	-5	-9	-13	-20
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	1	1	0	0	0	0	1	-0	0
Cash Flow From Financing Activity ⓘ +	7	-2	-0	-1	0	0	-6	-4	-6	8
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	2	1	3	3	-3	0	-1	13
Interest Paid ⓘ	0	-3	-2	-3	-3	-3	-3	-4	-5	-5
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	7	0	0	0	0	0	-0	-0	0	0
Net Cash Flow ⓘ	0	0	1	-0	-0	0	1	1	-0	-0

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	9.84	11.81	4.99	6.85	10.39	18.49	19.42	12.01	15.33	10.64
ROCE (%)	15.77	16.89	11.01	12.14	11.8	17.58	18.35	12.36	12.63	10.13
Asset Turnover Ratio	1.86	1.56	1.09	1.22	1.21	1.4	1.67	1.43	1.22	0.82
PAT to CFO Conversion(x)	-5	2.5	4	4	3	0.25	2.2	3.25	3	2.75
Working Capital Days
Receivable Days	87	107	144	133	133	121	114	130	137	164
Inventory Days	46	49	70	65	65	48	28	34	47	78
Payable Days	81	116	160	150	144	113	102	97	85	135

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Godavari Drugs Ltd FAQs

The current trading price of Godavari Drugs on 17-Apr-2026 16:59 is ₹125.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Godavari Drugs stood at ₹126.7 Cr

The latest P/E ratio of Godavari Drugs as of 16-Apr-2026 is 34.33.

The latest P/B ratio of Godavari Drugs as of 16-Apr-2026 is 2.60.

The 52-week high of Godavari Drugs is ₹129.8 and the 52-week low is ₹69.70.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Godavari Drugs is ₹98.15 ( Cr.) .

About Godavari Drugs Ltd

Godavari Drugs was incorporated as a private limited company on December 2, 1987 and subsequently converted into a public limited company on September 25, 1992. It was promoted by Ghanshyam Jaju, Mukund Kakani and PC Shrimal.

The company has set up a project to manufacture 180 TPA at Sulphamethoxazole (SMX) in 1988. The project is located at Maharashtra Industrial Development Corporation (MIDC), Nanded, a notified class â€˜Câ€™ backward district in Maharashtra. The project was fully commissioned on July 3, 1989.

The registered office of the company is located at Secunderabad in Andhra Pradesh and Mukund Kakani is its Managing Director.

Business area of the company

The companyâ€™s principal activity is to manufacture and sell bulk drugs. It undertakes contract manufacturing from various organizations. The products include Pyrazinamide and Ethambutol HCL.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Godavari Drugs Ltd (530317) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Godavari Drugs Share Price